Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions

XBiotech,Inc
Posted on: 03 Nov 17
Presentation to Discuss Novel Findings on MABp1 in the Prevention of Coronary Thrombosis

AUSTIN, Texas, Nov. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that research involving MABp1, the company's IL-1 alpha (IL-1[alpha]) antibody, will be featured in an oral presentation during the American Heart Association Scientific Sessions being held November 11-15 in Anaheim, California.  The presentation will provide evidence that IL-1[alpha] is associated with Neutrophil Extracellular Traps (NETs) and is involved in endothelial activation and thrombogenesis.

   
Title:   Neutrophil Extracellular Traps Increase Endothelial Activation and Thrombogenicity via IL-1[alpha] and NF-[kappa]B: Implications for Superficial Erosion 
   
Session:   Endothelial Dysfunction in Vascular Disease
   
Date:    Monday, November 13, 2017
   
Time:    5:45 p.m. - 5:55 p.m. (Pacific Time)
   
Location:   Anaheim Convention Center, Anaheim, CA
   

About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: XBiotech, Inc via GlobeNewswire
HUG#2147165
GlobeNewswire
globenewswire.com

Last updated on: 05/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.